Adocia - Asset Resilience Ratio
Adocia (ADOC) has an Asset Resilience Ratio of 0.00% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Adocia PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2023)
This chart shows how Adocia's Asset Resilience Ratio has changed over time. See how leveraged is Adocia's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Adocia's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Adocia stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Adocia maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Adocia Industry Peers by Asset Resilience Ratio
Compare Adocia's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Revolution Medicines Inc
NASDAQ:RVMD |
Biotechnology | 65.10% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Hugel Inc
KQ:145020 |
Biotechnology | 29.57% |
|
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX |
Biotechnology | 39.07% |
|
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076 |
Biotechnology | 2.30% |
|
Absci Corp
NASDAQ:ABSI |
Biotechnology | 59.86% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
|
Lifecome Biochemistry Co Ltd
SHE:002868 |
Biotechnology | 4.69% |
Annual Asset Resilience Ratio for Adocia (2016–2023)
The table below shows the annual Asset Resilience Ratio data for Adocia.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 16.10% | €4.02 Million ≈ $4.70 Million |
€24.96 Million ≈ $29.18 Million |
-40.80pp |
| 2022-12-31 | 56.91% | €17.42 Million ≈ $20.37 Million |
€30.61 Million ≈ $35.79 Million |
+6.46pp |
| 2021-12-31 | 50.45% | €15.16 Million ≈ $17.73 Million |
€30.05 Million ≈ $35.14 Million |
-11.80pp |
| 2020-12-31 | 62.25% | €28.11 Million ≈ $32.87 Million |
€45.17 Million ≈ $52.80 Million |
-8.23pp |
| 2019-12-31 | 70.47% | €43.66 Million ≈ $51.04 Million |
€61.95 Million ≈ $72.43 Million |
+13.59pp |
| 2018-12-31 | 56.88% | €39.84 Million ≈ $46.58 Million |
€70.04 Million ≈ $81.89 Million |
-7.81pp |
| 2017-12-31 | 64.69% | €34.78 Million ≈ $40.66 Million |
€53.76 Million ≈ $62.85 Million |
-8.96pp |
| 2016-12-31 | 73.65% | €58.04 Million ≈ $67.85 Million |
€78.80 Million ≈ $92.12 Million |
-- |
About Adocia
Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of act… Read more